Da Volterra
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
172 Rue De Charonne Bât B1, Paris, Ile-d...Phone Number
+33 158393220Website
www.davolterra.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Da Volterra
Headquartered in Paris (France), Da Volterra is a late-stage biopharmaceutical company developing innovative products to prevent intestinal microbiome dysbiosis in patients with cancer. The company's lead product-candidate, DAV132, is the world's most advanced product protecting against the clinical consequences of microbiome dysbiosis. It is in Phase 3 clinical trial and should be available for physicians and patients within a few years. DAV132 is a unique and first-in-class product designed to inactivate antibiotics as they reach the colon and prevent them from disrupting the intestinal microbiome. It has been proved effective in volunteers and patients. It is safe and does not impact the efficacy of antibiotics in treating or preventing infections. DAV132 is of particular interest to patients at risk of developing life-threatening complications caused by the use of antibiotics.Explore more
Da Volterra Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Da Volterra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Da Volterra had a recent Job posting/layoffs
Da Volterra, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Da Volterra launches new products
Check if Da Volterra has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Da Volterra
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Da Volterra has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Da Volterra is spiking on competitors!
Earning: See what the market has to say on Da Volterra recently announced quarterly report
Recommended Actions
Find VP level buyers at Da Volterra
Find 3 more new buyers
Company Profile Activity
Activity Insights
Da Volterra is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Da Volterra is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Da Volterra.
Da Volterra Tech Stack
A closer look at the technologies used by Da Volterra
Da Volterra News & Media
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
PARIS--(BUSINESS WIRE)-- #MicrobiotaProtectiveTherapy--Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients.Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy
PARIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/antibiotics?src=hash" target="_blank"gt;#antibioticslt;/agt;--Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective TherapyDa Volterra Announces Publication of Full Results from Clinical Trial of DAV132 to Prevent the Disruption of the Microbiome by Antibiotics
PARIS--(BUSINESS WIRE)--#antibiotics--Da Volterra publishes results of a clinical trial for DAV132, a product to protect the microbiota from disruption by antibiotics and prevent C. diff.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Da Volterra
Sign Up For FreeTo access detailed company insights
Headquartered in Paris (France), Da Volterra is a late-stage biopharmaceutical company developing innovative products to prevent intestinal microbiome dysbiosis in patients with cancer. The company's lead product-candidate, DAV132, is the world's most advanced product protecting against the clinical consequences of microbiome dysbiosis. It is in Ph... Read More
